Test your knowledge
Module 6: The impact of insomnia
Introduction
Adequate and high-quality sleep is crucial for our health and wellbeing, however unlike physical activity and a good diet, the need for healthy sleep is often underestimated.1 The long-term consequence of insufficient sleep is linked to a range of serious health conditions, including diabetes, depression and dementia.1 Research suggests that many individuals may be sleeping less than recommended, however the number of people suffering from chronic insomnia is underdiagnosed and overlooked.1-3
Learning objectives
By completing this module, you will increase your awareness and understanding of:
- the incidence of chronic insomnia in the UK and risk factors in different populations
- the direct impact of chronic insomnia on patients’ health and quality of life
- how chronic insomnia impacts the healthcare system and economy as a whole, and how we can begin to address the challenges
Multiple-choice questions to test your current knowledge
These questions will help you assess your current knowledge of this topic before you begin to work on the module. Your answers will be marked but will not count towards your final score. You will be asked the same questions again at the end of the module and will be able to download a learning certificate for your records upon completion.
Ready for the next step?
The burden of chronic insomnia on patients
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.4
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Lim D C, Najafi A et al. The need to promote sleep health in public health agendas across the globe. Lancet Public Health 2023;8(10):e820-e826
- Hafner M, Romanelli R J et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023
- Zhu G, Catt M et al. Objective sleep assessment in >80,000 UK mid‑life adults: associations with sociodemographic characteristics, physical activity and caffeine. PLoS One 2019;14(12):e0226220
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00658 | Date of preparation: September 2025
